Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical remains the leader in robotic surgical instrumentation. Its growth rate has slowed, its price declined, and its PE has come down.

Intuitive Surgical Still Growing, But More Slowly

Abbott Labs

Alcon Inc. - Registered Shares

Canopy Growth

Haemonetics

Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.

3 Medical Product Stocks Set to Beat on Earnings This Season

Investors were not happy with management's forward guidance for the rest of 2022.

Why Intuitive Surgical Stock Dropped 20.7% in April

The company's recent stock performance doesn't seem to reflect its long-term potential.

Intuitive Surgical's Shares Just Got More Attractive

Can Intuitive Surgical's Moat Get Even Wider?

Is It Too Late to Buy Intuitive Surgical Stock?

Could This 1 Detail Could Keep Intuitive Surgical Ahead of Rivals?

Pfizer

UnitedHealth Group

Walgreens

People will always need medical treatment regardless of what is going on with the economy, which makes stocks in the healthcare sector consistently reliable investments.

The 5 Best Healthcare Stocks To Own Right Now

The company talked about these potential problems on its earnings call.

2 of the Biggest Risks Intuitive Faces Right Now

Cardiovascular Systems

Zimmer Biomet Hlds

Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.

3 Medical Product Stocks Poised to Beat This Earnings Season

Adobe

Caterpillar

Chevron

Disney

JPMorgan Chase & Co

NextEra Energy

Procter & Gamble

Starbucks

Sherwin-Williams

This basket of growth, value, and income stocks is built to last

10 Unstoppable Stocks You'll Want in Your Corner if the Market Crashes

Wells Fargo writes that despite the beat in Q1, Intuitive Surgical Inc (NASDAQ: ISRG) sounded cautious on U.S. capital placements, given rising interest rates and inflationary pressure at hospitals.  "We think this commentary was partly driven by the need to.

Analysts Think Intuitive Surgical Painted 'Cautious Picture' For Procedure Guidance

The company's better-than-expected results couldn't counter management's cautious forecast.

Why Intuitive Surgical Stock Crumbled on Friday

The producer of surgical systems posts an earnings beat, but the stock pulls back after the company fails to significantly raise guidance.

Intuitive Surgical Stock Tanks. Blame the Cautious Guidance.

Intuitive Surgical, Inc. (NASDAQ: ISRG) shares are trading lower by 13.26% at $255.51 after the company reported first-quarter earnings results. Intuitive Surgical reported quarterly earnings of $1.13 per share which beat the analyst consensus estimate of $1.08.

Why Intuitive Surgical Shares Are Falling

Intuitive Surgical's (ISRG) first-quarter results reflect strong segmental performance.

Intuitive Surgical (ISRG) Q1 Earnings & Revenues Top Estimates

Intuitive Surgical Inc (NASDAQ: ISRG) reported Q1 FY22 adjusted EPS of $1.13, ahead of the consensus of $1.08. It reported revenues of $1.49 billion, +15% Y/Y, marginally ahead of Wall Street's estimate of $1.43 billion, driven by growth in da Vinci procedure volume and system.

Intuitive Surgical Q1 Slightly Ahead Of Expectations, Revises FY22 Outlook

Intuitive Surgical, Inc. (NASDAQ:ISRG ) Q1 2022 Earnings Conference Call April 21, 2022 4:30 PM ET Company Participants Brian King - Head, Investor Relations Gary Guthart - Chief Executive Officer Jamie Samath - Chief Financial Officer Conference Call Participants Amit Hazan - Goldman Sachs Rick Wise - Stifel Larry Biegelsen - Wells Fargo Drew Ranieri - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by and welcome to the Intuitive Q1 2022 Earnings Release. At this time, all participants are in listen-only mode.

Intuitive Surgical, Inc. (ISRG) CEO Gary Guthart on Q1 2022 Results - Earning Call Transcript

Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 5.61% and 3.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (ISRG) Tops Q1 Earnings and Revenue Estimates

Like the previous waves, a higher number of cases can overwhelm the healthcare services in certain geographies, resulting in the postponement of elective surgeries, obstructing the revenue growth seen over the recent quarters.

What To Expect From Intuitive Surgical's Q1?

Johnson & Johnson

Stryker

Stryker, Johnson & Johnson, and Intuitive Surgical can be counted on to be steady performers in your portfolio.

The Safest Healthcare Stocks in the World

Intuitive Surgical's (ISRG) first-quarter results are likely to reflect solid performance in the Instruments & Accessories segment.

What's in Store for Intuitive Surgical's (ISRG) Q1 Earnings?

Merck

Teladoc

These are the best healthcare stocks to invest in now. ISRG, MRK and TDOC can make great investments in the coming months.

3 Healthcare Stocks That Are Looking Even Healthier

Intuitive Surgical, Inc. (ISRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Intuitive Surgical, Inc. (ISRG) Q1 Earnings Expected to Decline

If things continue like they have been, the success won't stop anytime soon.

News for Intuitive Surgical Stock (ISRG)